PET Imaging in Recurrent Medullary Thyroid Carcinoma

Table 1

Basic study and patient characteristics.

Authors	Year	Country	MTC patients performing PET for suspected recurrence	Mean age (years)	% Male	Tracers used for PET or PET/CT
Treglia et al. [5]	2012	Italy	18	53	33%	FDG, FDOPA, and Gallium-68-DOTANOC/DOTATOC
Kauhanen et al. [6]	2011	Finland	19	52	53%	FDG and FDOPA
Ozkan et al. [7]	2011	Turkey	33	50	27%	FDG
Gómez-Camarero et al. [8]	2011	Spain	31	56	45%	FDG
Palyga et al. [9]	2010	Poland	8	56	50%	Gallium-68-DOTATATE
Jang et al. [10]	2010	Korea	16	51	56%	FDG and Carbon-11-methionine
Luster et al. [11]	2010	Germany	28	48	46%	FDOPA
Skoura et al. [12]	2010	Greece	32 (38 scans)	52	31%	FDG
Marzola et al. [13]	2010	Italy	18	51	44%	FDG and FDOPA
Bogsrud et al. [14]	2010	USA and Norway	29	50	55%	FDG
Conry et al. [15]	2010	UK and Singapore	18	54	72%	FDG and Gallium-68-DOTATATE
Beheshti et al. [16]	2009	Austria	19^*	59	38%	FDG and FDOPA
Faggiano et al. [17]	2009	Italy	26	NR	49%	FDG
Koopmans et al. [18]	2008	The Netherlands	21	56	48%	FDG and FDOPA
Rubello et al. [19]	2008	Italy	19	53	42%	FDG
Oudoux et al. [20]	2007	France	33	53	64%	FDG
Giraudet et al. [21]	2007	France	55	56	62%	FDG
Czepczyński et al. [22]	2007	Poland and Italy	13^*	50	57%	FDG
Beuthien-Baumann et al. [23]	2007	Germany	15	56	53%	FDG and FDOPA
Ong et al. [24]	2007	USA	28 (38 scans)	59	64%	FDG
Iagaru et al. [25]	2007	USA	13	48	46%	FDG
Gotthardt et al. [26]	2006	Germany and the Netherlands	26	45	58%	FDG
De Groot et al. [27]	2004	The Netherlands	26	51	58%	FDG
Szakáll et al. [28]	2002	Hungary	40	48	45%	FDG
Diehl et al. [29]	2001	Germany	85 (100 scans)	53	47%	FDG
Hoegerle et al. [30]	2001	Austria	10^*	57	55%	FDG and FDOPA
Brandt-Mainz et al. [31]	2000	Germany	17	NR	65%	FDG
Adams et al. [32]	1998	Germany	8	49	50%	FDG
Musholt et al. [33]	1997	USA and Germany	10	36	70%	FDG

NR: not reported; FDG: fluorine-18-fluorodeoxyglucose; FDOPA: fluorine-18-dihydroxyphenylalanine; ^*patients evaluated before primary surgery were excluded from the analysis.